Suchergebnisse - "Rangel, Jose David Gomez"

PubPharm (4)

1

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : final results of a randomised phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Yau, T. | Kaseb, A. | Cheng, A. | +19

2

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer : A randomized, double-blind, phase III study

enthalten in: Cancer medicine | 2023

von Chen, L. | Rangel, J. | Cil, T. | +15

3

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer : A randomized, double‐blind, phase III study

enthalten in: Cancer Medicine | 2023

von Chen, L. | Rangel, J. | Cil, T. | +15

4

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Kelley, R. | Rimassa, L. | Cheng, A. | +19

CommentIn: Lancet Oncol. 2022 Aug;23(8):962-963. - PMID 35798015

1
[1]